54 patents
Page 2 of 3
Utility
Methods for the Treatment of Abnormal Involuntary Movement Disorders
9 Dec 21
Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
David Stamler, Michael Huang
Filed: 12 Aug 21
Utility
Analogs of deutetrabenazine, their preparation and use
23 Nov 21
The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
Chengzhi Zhang, James Kerr
Filed: 25 Sep 19
Utility
Benzoquinolone Inhibitors of VMAT2
18 Nov 21
Andreas Sommer, Chengzhi Zhang
Filed: 31 Mar 21
Utility
Novel Pharmaceutical Formulations
21 Oct 21
The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
Filed: 12 Jan 21
Utility
Methods for the Treatment of Abnormal Involuntary Movement Disorders
9 Sep 21
Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
David Stamler, Michael Fangching Huang
Filed: 25 Mar 21
Utility
Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
12 Aug 21
The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
Filed: 25 Mar 21
Utility
Novel Pharmaceutical Formulations
8 Jul 21
The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
Filed: 3 Mar 21
Utility
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
15 Jun 21
The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
Filed: 13 Nov 19
Utility
Methods for the Treatment of Abnormal Involuntary Movement Disorders
20 May 21
Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
David Stamler, Michael Huang
Filed: 21 Jan 21
Utility
Substituted Phenethylamines with Serotoninergic and/or Norepinephrinergic Activity
8 Apr 21
Thomas G. Gant, Sepehr Sarshar, Soon Hyung Woo
Filed: 21 Aug 20
Utility
Pharmaceutical formulations
6 Apr 21
The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury
Filed: 12 Jul 19
Utility
Methods for the treatment of abnormal involuntary movement disorders
30 Mar 21
Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
David Stamler, Michael Fangching Huang
Filed: 19 Jul 18
Utility
Methods of Manufacturing Benzoquinoline Compounds
4 Nov 20
Chengzhi Zhang
Filed: 14 Apr 20
Utility
Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
4 Nov 20
Thomas G. Gant, Manouchehr Shahbaz
Filed: 16 Mar 20
Utility
Methods of Manufacturing Benzoquinoline Compounds
21 Oct 20
Chengzhi Zhang
Filed: 11 Nov 19
Utility
Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
16 Sep 20
The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
Filed: 12 Nov 19
Utility
Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds
16 Sep 20
Chengzhi ZHANG
Filed: 19 Apr 20
Utility
Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
9 Sep 20
David Stamler
Filed: 25 Sep 19
Utility
Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
12 Aug 20
The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
Filed: 26 Apr 20
Utility
Dimethoxyphenyl inhibitors of vesicular monoamine transporter 2
27 Jul 20
Chengzhi Zhang
Filed: 16 Feb 16